Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Children Conceived after Fertility Treatments are at Increased Risk for Pediatric Cancers

By Ben-Gurion University of the Negev | April 25, 2017

Ben-Gurion University of the Negev (BGU) researchers have found that babies born from mothers who underwent fertility treatments are at increased risk of developing many types of pediatric cancers and tumors (neoplasms).

According to the American Cancer Society, the most common pediatric neoplasms are leukemia, brain and spinal cord tumors, neuroblastomas, Wilms tumors, and lymphoma, including both Hodgkin and non-Hodgkin.

The study, published in the March issue of the American Journal of Obstetrics & Gynecology, was a population-based cohort analysis of babies born between 1991 and 2013 at Soroka University Medical Center in Beer-Sheva, Israel, with follow-up to age 18.

“In Israel, all fertility interventions, which include in vitro fertilization (IVF) and ovulation induction (OI), are fully covered by insurance, enabling citizens of all backgrounds access to these treatments,” says Prof. Eyal Sheiner, M.D., Ph.D., vice dean of the BGU Faculty of Health Sciences (FOHS), member of its Department of Obstetrics and Gynecology, and a physician at Soroka.

Of the 242,187 newborn infants in the study, 237,863 (98.3 percent) were conceived spontaneously; 2,603 (1.1 percent) were conceived after in vitro fertilization, and 1,721 (0.7 percent) were conceived after ovulation induction treatments.

During the follow-up period of approximately 10.6 years, 1,498 neoplasms (0.6 percent) were diagnosed. The incidence rate for neoplasms was highest among children either after IVF (1.5/1000) and somewhat lower for OI births (1.0/1000) as compared to that of naturally conceived children (.59/1000).

“The research concludes that the association between IVF and total pediatric neoplasms and malignancies is significant,” Prof. Sheiner says. “With increasing numbers of offspring conceived after fertility treatments, it is important to follow up on their health.”

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE